255641001: Caffeine (substance)

SNOMED CT Concept\Substance\...

\Substance categorized by disposition\Substance with effector mechanism of action (substance)\Enzyme inhibitor\Hydrolase inhibitor\Phosphodiesterase inhibitor\Caffeine

\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Respiratory system agent (substance)\Methyl xanthine\Caffeine
\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Central nervous system agent (substance)\Psychoactive substance (substance)\Psychotropic agent (substance)\Psychostimulant (substance)\Caffeine
\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Central nervous system agent (substance)\Stimulant (substance)\Psychostimulant (substance)\Caffeine

\Substance categorised by structure\Chemical\Chemical categorized by structure (substance)\...

\Nitrogen and/or nitrogen compound (substance)\Nitrogen compound\Organic nitrogen compound\Purine and/or purine derivative\Xanthine and/or xanthine derivative (substance)\Xanthine derivative (substance)\Methyl xanthine\Caffeine

\Substance categorized functionally\Phytochemical\Caffeine

\Material (substance)\Natural material\Organic natural material\Plant material\Phytochemical\Caffeine

\Biological substance\Organic natural material\Plant material\Phytochemical\Caffeine

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2002. Module: SNOMED CT core

Descriptions:

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
Caffeine	Is a	Phytochemical	true	Inferred relationship	Some
Caffeine	Is a	Xanthine	false	Inferred relationship	Some
Caffeine	Is a	Central nervous system agent (substance)	false	Inferred relationship	Some
Caffeine	Is a	allergène médicamenteux	false	Inferred relationship	Some
Caffeine	Is a	Methyl xanthine	true	Inferred relationship	Some
Caffeine	Is a	Central respiratory stimulant	false	Inferred relationship	Some
Caffeine	Is a	Phosphodiesterase inhibitor	true	Inferred relationship	Some
Caffeine	This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context.	Phosphodiesterase inhibitor (disposition)	true	Inferred relationship	Some
Caffeine	Is a	Enzyme inhibitor	false	Inferred relationship	Some
Caffeine	Is a	Psychostimulant (substance)	true	Inferred relationship	Some

Inbound Relationships	Type	Active	Source	Characteristic	Refinability	Group
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	2
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	2
Product containing precisely caffeine 100 milligram and ergotamine tartrate 1 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	1
Product containing precisely caffeine 100 milligram and ergotamine tartrate 1 milligram/1 each conventional release oral tablet (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Caffeine 25 mg and paracetamol 450 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	1
Caffeine 25 mg and paracetamol 450 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	3
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	3
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	2
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	2
Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	2
Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	2
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	3
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	3
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	3
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	3
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	3
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	3
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	2
Product containing precisely caffeine 65 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	1
Product containing precisely caffeine 65 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Product containing precisely caffeine 30 milligram and paracetamol 450 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	1
Product containing precisely caffeine 30 milligram and paracetamol 450 milligram/1 each conventional release oral tablet (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	2
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	2
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	1
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	1
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Product containing precisely caffeine 100 milligram and ergotamine tartrate 1 milligram/1 each conventional release oral tablet (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	2
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	1
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	1
Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	2
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	2
Product containing precisely aspirin 250 milligram and caffeine 65 milligram and paracetamol 250 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	1
Product containing precisely aspirin 250 milligram and caffeine 65 milligram and paracetamol 250 milligram/1 each conventional release oral tablet (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	2
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	3
Product containing precisely aspirin 250 milligram and caffeine 65 milligram and paracetamol 250 milligram/1 each conventional release oral tablet (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	3
Caffeine monohydrate (substance)	Is a	False	Caffeine	Inferred relationship	Some
Caffeine hydrate	Is a	False	Caffeine	Inferred relationship	Some
Change in provision of caffeine.	Direct substance	True	Caffeine	Inferred relationship	Some	1
Caffeine citrate	This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged.	True	Caffeine	Inferred relationship	Some
Caffeinated coffee	This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged.	False	Caffeine	Inferred relationship	Some
Caffeine hydrate	This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged.	True	Caffeine	Inferred relationship	Some
Caffeine monohydrate (substance)	This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged.	True	Caffeine	Inferred relationship	Some
Caffeinated soft drinks	This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged.	False	Caffeine	Inferred relationship	Some
Product containing caffeine and codeine and paracetamol in oral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing caffeine and codeine and paracetamol (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Caffeine 15 mg and codeine phosphate 30 mg and paracetamol 300 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Caffeine 15 mg and codeine phosphate 15 mg and paracetamol 300 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	3
Caffeine- and sodium benzoate-containing product in parenteral dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	2
Caffeine 100 mg and ergotamine tartrate 2 mg rectal suppository	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Caffeine 100 mg and ergotamine tartrate 2 mg rectal suppository	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Caffeine	Inferred relationship	Some	1
Product containing caffeine and ergotamine in oral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Caffeine	Inferred relationship	Some	1
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	3
Product containing aspirin and caffeine and paracetamol in oral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	2
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	2
Aspirin- and butalbital- and caffeine-containing product in oral dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing aspirin and butalbital and caffeine and codeine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing aspirin and caffeine and orphenadrine in oral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing aspirin and caffeine and dihydrocodeine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing aspirin and caffeine and dihydrocodeine in oral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing precisely caffeine 100 milligram and ergotamine tartrate 1 milligram/1 each conventional release oral tablet (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	2
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	2
Aspirin- and butalbital- and caffeine- and codeine-containing product in oral dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	3
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	3
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	2
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Caffeine	Inferred relationship	Some	1
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	2
Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	2
Caffeine 15 mg and codeine phosphate 15 mg and paracetamol 300 mg oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	3
Product containing precisely caffeine 30 milligram and paracetamol 450 milligram/1 each conventional release oral tablet (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Caffeine	Inferred relationship	Some	1
Caffeine 25 mg and paracetamol 450 mg oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	2
Caffeine 15 mg and codeine phosphate 30 mg and paracetamol 300 mg oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Caffeine	Inferred relationship	Some	1
Product containing precisely aspirin 250 milligram and caffeine 65 milligram and paracetamol 250 milligram/1 each conventional release oral tablet (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	3
Product containing precisely caffeine 65 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Caffeine	Inferred relationship	Some	1
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	3
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	3
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Caffeine	Inferred relationship	Some	3
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Caffeine	Inferred relationship	Some	1
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Caffeine	Inferred relationship	Some	1
Product containing butalbital and caffeine and codeine and paracetamol (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing butalbital and caffeine and codeine and paracetamol in oral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing caffeine and dihydrocodeine and paracetamol (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing caffeine and dihydrocodeine and paracetamol in oral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Caffeine	Inferred relationship	Some	1
Product containing caffeine and isometheptene and paracetamol (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing aspirin and caffeine and dextropropoxyphene in oral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing butalbital and caffeine and paracetamol in oral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Caffeine- and ergotamine-containing product in rectal dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing caffeine and paracetamol in oral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing aspirin and caffeine and dextropropoxyphene (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1

Start Page 2 of 4 Next End

This concept is not in any reference sets

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
380891010	Caffeine	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
646709011	Caffeine (substance)	en	Fully specified name	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
56441000195115	caffeina	it	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module
796671000172110	caféine	fr	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module
71441000195114	Coffein	de	Synonym (core metadata concept)	Active	Entire term case sensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module
659461000274116	Koffein	de	Synonym (core metadata concept)	Active	Entire term case sensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module